Transcatheter valves are a viable option for degenerative surgical mitral bioprostheses.
Asaad A KhanGeorge D DangasPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2020)
Repeat surgery is the ideal choice for degenerated bioprosthetic mitral valves. Percutaneous valve-in-valve (ViV) replacement for the treatment of degenerated bioprostheses has emerged as an alternative to open surgery in patients who are at high risk of surgical complications. Joseph et al have described the feasibility and long-term outcomes of Melody ViV Implantation for bioprosthetic mitral valve dysfunction in high-risk population.
Keyphrases
- mitral valve
- minimally invasive
- aortic valve replacement
- aortic stenosis
- ejection fraction
- aortic valve
- left atrial
- left ventricular
- coronary artery bypass
- end stage renal disease
- transcatheter aortic valve implantation
- transcatheter aortic valve replacement
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- heart failure
- risk factors
- patient reported outcomes
- combination therapy
- catheter ablation